Clinical trials · Washington, D.C., DC
HER2-negative Breast Cancer clinical trials in Washington, D.C.
We’re tracking 29 recruiting her2-negative breast cancer studies with a site in or near Washington, D.C. — including Phase 1, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
Baltimore, MarylandAges 18 years+ - NCT06764940RecruitingPhase 2
Utidelone and capecitabine for HER2-negative breast cancer with brain metastases
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
Baltimore, MarylandAges 18 years+ - NCT02422641RecruitingPhase 2
High-dose methotrexate for breast cancer in the brain lining
This Phase 2 trial tests whether giving high-dose methotrexate into the bloodstream can help treat breast cancer that has spread to the thin lining covering the brain and spinal cord. It may help reduce cancer in the leptomeningeal (brain-lining) area and control symptoms.
Baltimore, MarylandAges 18 years+ - NCT07391774RecruitingPhase 3
Hormone therapy with or without chemo for early breast cancer
This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.
Baltimore, MarylandAges 18 years+ - NCT05029999RecruitingPhase 1
Test drugs for HER2-negative advanced breast cancer
This Phase 1 trial tests a combination of immune-targeting drugs (a CD40 medicine and a substance that helps immune cells act) plus chemotherapy in people with HER2-negative advanced breast cancer that has progressed. It aims to find a safer dose and see whether the treatment can shrink tumors or slow the cancer.
Baltimore, MarylandAges 18–99
Hear when a new HER2-negative Breast Cancer trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
HER2-negative Breast Cancer trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting her2-negative breast cancer studies listed above.
- Greater Baltimore Medical Center
- Johns Hopkins University
- Local Institution - 1035
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- The Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine
- University of Maryland Shore Medical Center
- University of Maryland/Greenebaum Cancer Center
What taking part in a her2-negative breast cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting her2-negative breast cancer studies in District of Columbia.
Common questions
- Are there her2-negative breast cancer clinical trials near Washington, D.C.?
- Yes. We're currently tracking 29 recruiting her2-negative breast cancer studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a her2-negative breast cancer study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a her2-negative breast cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New her2-negative breast cancer studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.